loader2
Partner With Us NRI
Zydus Lifesciences Ltd>
  • CMP : 922.2 Chg : -14.85 (-1.58%)
  • Target : 500.0 (16.28%)
  • Target Period : 12-18 Month

04 Feb 2023

Decent performance; US pipeline, India traction key…

About The Stock

Zydus is a leading pharma company with family pedigree having a presence in domestic branded formulations, US generics and is in the process of repurposing itself into niche areas of specialty pharmaceuticals, biosimilars and vaccines.

  • Q3FY23 revenue break-up – US: 46.3%, India: 29.6%, Wellness: 9.9%, Europe & emerging markets including countries in LatAm, Asia Pacific & Africa: 14.2%
  • Zydus is the fourth largest pharma company in India with 14 brands among Top 300 pharma brands in India and nine with ₹ 100 crore+ sales
Q3FY23

Zydus delivered good set of numbers, which beat our estimates.

  • Revenues grew 19.8% YoY at ₹ 4362 crore
  • EBITDA grew 27.2% YoY to ₹ 956 crore. EBITDA margins improved 127 bps YoY to 21.9%
  • Adjusted net profit rose 22.8% YoY to ₹ 622.5 crore
What should Investors do?

Zydus Life’s share price has grown at 18% CAGR over the past three years.

  • We upgrade the stock from HOLD to BUY for improved risk-reward proposition as we see 1) consistency from US business in terms of continued traction in base business and new launches momentum (post Moraiya EIR) and 2) continued traction in Wellness and India formulations
Target Price and Valuation

Valued at ₹ 500 i.e., 14x FY25E EPS of 35.5

Key Triggers for future price performance
  • Zydus plans to venture into complex injectable and niche orphan drugs in US. Complex launches are likely to provide meaningful traction from FY24
  • Moraiya launch momentum and base business growth (impending competition in Asacol) in the US
  • India formulations business is likely to stabilise as the company has optically initiated restructuring of business by rationalising slow moving SKUs
  • Pipeline of innovative products like Saroglitazar Magnesium, Desidustat, anti-malarial compound, biologics and 505(b)(2) specialty initiatives
Alternate Stock Idea

Apart from Zydus, in our healthcare coverage we like Cipla.

  • Cipla has a long-drawn strategy of targeting four verticals viz. One-India, South Africa & EMs, US generics & specialty and lung leadership
  • BUY with a target price of ₹ 1290

Key Financial Summary

Particulars FY20 FY21 FY22 5 Year CAGR(FY17-FY22) FY23E FY24E FY25E 2 Year CAGR (FY23E-FY25E)
Revenues 14,253.1 14,403.5 15,265.2 9.7 17,361.7 18,956.5 20,246.8 8.0
EBITDA 2,742.0 3,387.1 3,340.7 11.9 3,620.5 3,980.9 4,251.8 8.4
EBITDA margins (%) 19.2 23.5 21.9 - 20.9 21.0 21.0 -
Net Profit 1,430.1 2,390.1 2,149.2 4.0 2,311.2 2,764.9 3,638.5 25.5
EPS (|) 14.0 23.3 21.0 - 22.6 27.0 35.5 -
PE (x) 37.4 20.0 19.6 - 19.1 15.9 12.1 -
EV to EBITDA (x) 18.6 14.1 14.1 - 12.7 11.0 9.1 -
RoE (%) 13.8 18.4 12.6 - 12.1 12.8 14.6 -
RoCE (%) 10.7 13.8 12.0 - 12.3 12.3 12.0 -
Source: Company, ICICI Direct Research

Key takeaways of recent quarter & conference call highlights

Q3FY23 Earnings Summary:Good set of numbers led by solid performance on all the parameters.

  • Revenues grew 19.8% YoY to | 4362 crore. Growth was driven by the US followed by India business. Segmental mix includes India sales, which increased 14.2% YoY to | 1231.6 crore on the back of market share gains and improved ranking in gynaecology, anti-diabetic and nutraceutical portfolio. US formulations revenues increased 29.3% YoY to | 1925 crore, aided by volume expansion in base portfolio and some impact of seasonality. Emerging markets revenues increased 5.6% YoY to | 307.8 crore, on the back of robust performance across key markets. Zydus Wellness’ revenues increased 7.8% YoY to | 412 crore on the back of firm market share in key brands viz. Glucon-D, Nycil and EverYuth (Scrub, Peel-Off). On operational front, EBITDA showed growth of 27.2% YoY to | 956 crore whereas EBITDA margins improved 127 bps YoY to 21.9% despite higher R&D and US related risk evolution and mitigation study (REMS) programme cost. Adjusted PAT improved 22.8% YoY to | 622.5 crore
  • The company’s performance was a beat against our estimates on all fronts. India business continues to do well with market share gain in key therapies. Timely launches and volumes supported US growth. Consumer wellness business maintained a dominating market position in key brands despite the difficult environment. We continue to monitor India and US business momentum as historically these two markets have been persistent laggards vis-à-vis peers, thus having direct implications on its muted valuations

Q3FY23 Earnings Conference Call highlights:

Business mix:

  • The overall performance was led by robust growth across businesses. US contributed 46% to the topline followed by India formulation 30%, Consumer wellness 10% and EM 7% during the period
  • US formulation business – Received final approval for Estradiol Transdermal System, which will be manufactured from Moraiya site
  • It filed first ANDA filed from the new oral solids formulations manufacturing facility in Ahmedabad SEZ (SEZ II)
  • In India formulation business - The patient base of the Lipaglyn brand increased by 45% in CY22, thus extending its reach
  • Consumer Wellness – The company has undertaken price increase in order to mitigate inflation, which has cooled down compared to the previous quarters except milk, where it still remains high

Financial metric:

  • The operational performance was largely attributable to robust double digit growth in India and US formulations businesses
  • It undertook price increase, which would reflect in Q4FY24
  • It also incurred one-time REMS setup cost of US$8 million during the quarter for an upcoming launch, where the opportunities are likely to come in from H2FY24
  • R&D spend during the quarter was at 7.9% for which management has guided to remain at 8.5-9% in the near term. R&D is expected to be inclined more towards NCE’s and biologics.
  • Currently 30% of R&D spends is towards specialty and new ventures

Launches:

  • It became the first player to launch Topiramate ER capsules (gTrokendi) in the US in January 2023
  • It plans to launch two transdermal products in FY24
  • Biosimilar focus remains for two to three launches in the next two years in India and other semi-regulated markets

Other highlights:

  • Established products of the company have largely done better than the markets
  • US business to remain strong due to REMS programme and new launches
  • The management expects further value addition from its recent launch of Topiramate ER capsules (gTrokendi) in US
  • They have guided that performance from Biologics/Biosimilar business is stable in India in terms of both revenues and profits
  • The company is taking calibrated measures to develop specialty chemical business
  • Focus remains on inorganics opportunities
  • Revlimid is expected to see higher sales in Q4FY23.
  • Capex for the quarter was at | 255 crore. It expects to continue with | 800-900 crore of run rate for the coming years

Disclaimer

ANALYST CERTIFICATION

I/We, Siddhant Khandekar - Inter CA, Kushal Shah – CFA L1, CFP, Utkarsh Jain - MBA, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India’s largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. (“associates”), the details in respect of which are available on www.icicibank.com. 

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. 

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stocks price movement, outstanding positions, trading volume etc as opposed to focusing on a companys fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports. 

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. 

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research. 

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. 

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. 

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months. 

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction. 

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months. 

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report. 

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. 

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report. 

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according -to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts valuation for a stock

Buy: >15%

Hold: -5%to 15%;

Reduce: -15% to -5%;

Sell: <-15% 

Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

 

 

ICICI Direct Research Desk,

ICICI Securities Limited,

1st Floor, Akruti Trade Centre,

Road No 7, MIDC,

Andheri (East)

Mumbai – 400 093

 

 

research@icicidirect.com

Read More